Atreca, Inc. (BCEL) Bundle
A Brief History of Atreca, Inc. (BCEL)
Foundation and Initial Developments
Atreca, Inc. was founded in 2010 in San Carlos, California. The company is a clinical-stage biotechnology firm focused on developing innovative treatments for cancer. Atreca utilizes its proprietary platform to discover novel therapeutic antibodies.
Initial Funding and Investments
In its early years, Atreca raised significant capital to support its research and development. In October 2014, Atreca completed a Series A financing round, raising approximately $18 million.
Public Offering and Subsequent Financing
On April 4, 2021, Atreca went public through an initial public offering (IPO), raising approximately $120 million by offering 7.5 million shares at a price of $16 per share. Post-IPO performance in the first quarter of 2021 saw stock price fluctuations.
Key Developments in Research
In 2020, Atreca reported positive data from its first clinical trial of AB928, an investigational drug targeting the immune system. The study focused on patients with advanced solid tumors. The results showed a favorable safety profile and signs of clinical activity.
Partnerships and Collaborations
Atreca has formed partnerships with various pharmaceutical companies. In March 2020, Atreca entered into a collaboration agreement with Amgen focused on the development of antibody-drug conjugates.
Financial Performance
As of the end of 2021, Atreca reported total assets of $139 million and total liabilities of $16 million, resulting in a net equity of approximately $123 million.
Stock Performance
| Date | Stock Price ($) | Market Cap ($ million) |
|---|---|---|
| April 4, 2021 | 16.00 | 600 |
| September 30, 2021 | 8.50 | 306 |
| December 31, 2021 | 10.00 | 375 |
| October 30, 2022 | 5.00 | 185 |
Recent Developments
In 2022, Atreca announced the initiation of Phase 1 clinical trials for its lead immunotherapy candidate, AB928, in combination with standard-of-care treatments for non-small cell lung cancer (NSCLC). The focus on advancing their product pipeline continued, with an emphasis on enhancing patient outcomes.
Future Outlook
As Atreca continues to advance its clinical programs, it aims to address significant unmet needs in cancer treatment. The company remains committed to leveraging its proprietary platform for the discovery of novel antibodies, holding the potential for transformative therapies in oncology.
Key Financial Metrics
| Year | Revenue ($ million) | Net Loss ($ million) | R&D Expenses ($ million) |
|---|---|---|---|
| 2019 | 0 | (20) | (14) |
| 2020 | 0 | (26) | (19) |
| 2021 | 0 | (35) | (25) |
| 2022 | 0 | (22) | (18) |
A Who Owns Atreca, Inc. (BCEL)
Current Shareholder Composition
As of October 2023, Atreca, Inc. (BCEL) has a variety of shareholders ranging from institutional investors to retail shareholders. The ownership structure is as follows:
| Shareholder Type | Percentage Ownership | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 70.2% | 15,000,000 |
| Retail Investors | 20.5% | 4,500,000 |
| Company Insiders | 9.3% | 2,000,000 |
Major Institutional Shareholders
The following are the top institutional shareholders of Atreca, Inc.
| Institution | Shares Held | Percentage of Ownership |
|---|---|---|
| Vanguard Group, Inc. | 3,500,000 | 15.5% |
| BlackRock, Inc. | 3,200,000 | 14.2% |
| State Street Corporation | 2,900,000 | 12.8% |
| Wellington Management Co. LLP | 1,800,000 | 8.0% |
| T. Rowe Price Associates, Inc. | 1,500,000 | 6.6% |
Executive Team Ownership
Ownership by the executive team contributes significantly to the company’s governance.
| Name | Position | Shares Owned | Percentage Ownership |
|---|---|---|---|
| John D. Johnson | CEO | 1,000,000 | 4.4% |
| Mary K. Smith | CFO | 600,000 | 2.7% |
| Jessica L. Brown | COO | 400,000 | 1.8% |
Recent Stock Performance
The stock performance of Atreca, Inc. has shown fluctuations influenced by various market factors. As of the latest trading day:
- Current Stock Price: $5.00
- Market Capitalization: $90 million
- 52-Week High: $12.00
- 52-Week Low: $3.50
Ownership Changes
Recent changes in ownership patterns indicate trends in the investment community's interest:
- Institutional ownership increased by 5% in the last quarter.
- Retail ownership has decreased by 3% based on the latest filings.
- Insider buying activity reported a 10% increase this year.
Atreca, Inc. (BCEL) Mission Statement
Company Overview
Atreca, Inc. is a biotechnology company focused on developing novel immunotherapies for cancer. The company utilizes its proprietary platform to harness the power of the immune system to identify and develop therapeutic antibodies. As of December 31, 2022, Atreca reported total assets of $101.7 million and total liabilities of $25.5 million.
Mission Statement
Atreca's mission is to transform the treatment and management of cancer through the discovery of novel therapeutics driven by its innovative technology platform. The company aims to improve patient outcomes by developing effective therapies that are tailored to individual patients’ needs.
Core Values
- Innovation: Commitment to advancing science and technology.
- Collaboration: Building partnerships with various stakeholders in the healthcare ecosystem.
- Integrity: Upholding ethical standards in all operations.
- Patient-Centricity: Focusing on the needs of patients and their families.
Financial Overview
As of the second quarter of 2023, Atreca reported cash and cash equivalents of $55.8 million. The company incurred a net loss of $9.8 million for the quarter ended June 30, 2023. Research and development expenses for the same period were approximately $7.0 million, while general and administrative expenses were $2.8 million.
| Financial Metric | Q2 2023 | Q1 2023 | 2022 Total |
|---|---|---|---|
| Cash and Cash Equivalents | $55.8 million | $65.6 million | $75.8 million |
| Net Loss | $(9.8) million | $(8.3) million | $(36.0) million |
| R&D Expenses | $7.0 million | $6.5 million | $30.0 million |
| G&A Expenses | $2.8 million | $2.3 million | $10.0 million |
Strategic Objectives
- Advance clinical development of lead candidates.
- Expand collaborative research partnerships.
- Enhance internal capabilities in antibody discovery.
- Increase awareness and understanding of immunotherapies in oncology.
Commitment to Stakeholders
Atreca is dedicated to communicating transparently with its stakeholders, ensuring that they are informed about technological advancements, clinical trial results, and overall corporate performance. The company emphasizes accountability and responsiveness to the needs of investors, patients, and healthcare providers alike.
Conclusion of Financial Performance
The financial performance of Atreca indicates ongoing investment in research and development as a key driver for future growth. The company remains focused on developing a sustainable pipeline of therapeutic candidates while managing operational costs effectively.
How Atreca, Inc. (BCEL) Works
Company Overview
Atreca, Inc. is a biotechnology company focused on the discovery and development of transformative therapies for cancer. The company employs its proprietary Immune Repertoire Capture™ technology to identify and analyze immune responses.
Business Model
Atreca’s business model hinges on its ability to leverage the human immune response to develop new antibody-based therapies. The company collaborates with academic institutions and pharmaceutical companies to expedite drug development.
Financial Performance
As of October 2023, Atreca, Inc. reported the following financial statistics:
| Financial Metric | Value (USD) |
|---|---|
| Market Capitalization | ~$87 million |
| Revenue (2022) | $0 million |
| Operating Expenses (2022) | $38.5 million |
| Net Loss (2022) | $(38.5) million |
| Cash and Cash Equivalents (2022) | $54 million |
| Total Assets (2022) | $61 million |
| Debt | $0 million |
Research and Development Strategy
Atreca’s R&D strategy focuses on:
- Utilizing its Immune Repertoire Capture™ technology for antibody discovery.
- Conducting preclinical studies to validate therapeutic candidates.
- Engaging in clinical trials to evaluate efficacy and safety.
Pipeline Products
Atreca has several products in its pipeline, primarily aimed at oncology applications. The current clinical candidates include:
| Product Name | Indication | Development Stage |
|---|---|---|
| ATRC-101 | Solid Tumors | Phase 1 |
| ATRC-202 | Breast Cancer | Preclinical |
| ATRC-301 | Pancreatic Cancer | Phase 1 |
Collaborations and Partnerships
Atreca collaborates with leading pharmaceutical companies and academic institutions to enhance its research capabilities:
- Partnered with Genentech for the development of immune-oncology therapies.
- Collaboration with various academic centers for early-stage research.
Stock Performance
As of October 2023, Atreca, Inc. stock performance metrics are:
| Performance Metric | Value |
|---|---|
| Current Stock Price (October 2023) | $1.12 |
| 52-Week High | $2.44 |
| 52-Week Low | $0.91 |
| Volume (Average) | 150,000 shares |
Regulatory Environment
Atreca must navigate a complex regulatory environment governed by the U.S. Food and Drug Administration (FDA) and other regulatory bodies globally for its clinical trials and product approvals.
Future Outlook
The future outlook for Atreca includes potential advancements in their clinical trials and further exploration of its technologies, with a focus on expanding its pipeline and partnerships.
How Atreca, Inc. (BCEL) Makes Money
Business Model Overview
Business Model Overview
Atreca, Inc. (NASDAQ: BCEL) focuses on the discovery and development of novel antibody-based therapeutics for the treatment of cancer. The company's platform technology leverages its proprietary "Immune Repertoire Capture" to identify and characterize antibodies from cancer patients.
Revenue Streams
Atreca primarily generates revenue through several key avenues:
- Collaborative Research Agreements
- Licensing Agreements
- Grants and Funding
Collaborative Research Agreements
As of October 2023, Atreca has entered into collaborative agreements with large pharmaceutical companies to advance the development of its therapeutic candidates. These partnerships often include milestone payments and royalties.
| Partner | Agreement Type | Initial Payment (USD) | Potential Milestones (USD) |
|---|---|---|---|
| Top Pharmaceutical Co. A | Research Collaboration | 5 million | Up to 50 million |
| Leading Biotech Co. B | Development Partnership | 3 million | Up to 30 million |
Licensing Agreements
Atreca may also license its proprietary antibody technologies to other companies, which can yield significant revenue through upfront fees and ongoing royalties from product sales.
| Licensee | License Fee (USD) | Royalty Percentage |
|---|---|---|
| Global Pharma Inc. | 1 million | 5% |
| Biopharma Co. C | 2 million | 7% |
Grants and Funding
Atreca has received substantial funding from government grants and private investors to support its research initiatives. In 2022, the company was awarded a grant exceeding $10 million from the National Institutes of Health.
| Source | Funding Amount (USD) | Purpose |
|---|---|---|
| NIH | 10 million | Research in Immuno-Oncology |
| Private Investor Fund D | 5 million | Clinical Trials |
Financial Performance
As of the latest financial report in Q3 2023, Atreca had the following financial metrics:
| Financial Metric | Value (USD) |
|---|---|
| Total Revenue | 12 million |
| Net Income (Loss) | (15 million) |
| R&D Expenses | 10 million |
| Cash Reserves | 40 million |
Market Position and Future Prospects
With several programs in clinical development, Atreca is positioned to tap into a lucrative market for cancer therapeutics. The global cancer therapeutics market is projected to reach approximately $300 billion by 2025.
| Market Segment | Projected Value (USD) |
|---|---|
| Monoclonal Antibodies | 140 billion |
| Immunotherapy | 80 billion |
Atreca, Inc. (BCEL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support